A Pharmacist's Guide to Medical Marijuana: Uses, Risks, and Legal Complexity
As of 2007, 11 US states had legalized medical marijuana for conditions including nausea, weight loss, spasticity, and pain, but pharmacists had limited guidance on interactions and patient counseling.
Quick Facts
What This Study Found
This review outlined the pharmacological, therapeutic, and legal landscape of medical marijuana for pharmacists as of 2007.
The authors identified five general indications with varying levels of evidence: chemotherapy-induced nausea, weight loss from debilitating illness (HIV, cancer), spasticity from neurological diseases, pain syndromes, and other uses including glaucoma.
The review cataloged known adverse effects across psychiatric, cardiovascular, respiratory, and immunologic domains, and highlighted potential drug-drug interactions and disease-state interactions that pharmacists should be aware of.
A key practical challenge was noted: since marijuana remained a Schedule I controlled substance under federal law, patients using state-legal medical marijuana might never interact with a pharmacist, creating a gap in patient safety.
Key Numbers
Over 460 active chemicals and 60+ unique cannabinoids in marijuana. 11 US states had legalized medical marijuana as of 2007. Five general medical indications were identified.
How They Did This
Narrative review of published literature on marijuana pharmacology, therapeutic uses, safety profile, drug interactions, and legal status. Organized as a practical reference for pharmacists.
Why This Research Matters
This review highlighted a unique problem in medical marijuana: it occupied a legal gray zone where patients used it medicinally but without the pharmaceutical infrastructure (pharmacist counseling, interaction screening, quality control) that exists for other medications.
The Bigger Picture
The challenges identified in this 2007 review, including the federal-state legal conflict, lack of pharmacist involvement, and limited interaction data, remain relevant as medical cannabis programs have expanded to the majority of US states.
What This Study Doesn't Tell Us
As a narrative review from 2007, the evidence base was limited. The legal landscape has changed dramatically since publication. Drug interaction data for cannabis remained sparse and largely theoretical.
Questions This Raises
- ?How should pharmacists integrate medical marijuana into drug interaction screening?
- ?Can standardized cannabis products be developed that fit into existing pharmaceutical frameworks?
Trust & Context
- Key Stat:
- 11 US states had legalized medical marijuana by 2007, but pharmacists had limited guidance
- Evidence Grade:
- This is a narrative review providing an overview for practitioners. It synthesizes existing knowledge but does not add new data.
- Study Age:
- Published in 2007. The US landscape has changed dramatically: as of 2024, over 40 states have some form of legal medical cannabis, and several have recreational legalization.
- Original Title:
- Medical marijuana and the developing role of the pharmacist.
- Published In:
- American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 64(10), 1037-44 (2007)
- Database ID:
- RTHC-00291
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why are pharmacists relevant to medical marijuana?
Pharmacists are drug interaction experts who screen for dangerous combinations. Since medical marijuana patients often take other medications, pharmacist involvement could improve safety. However, marijuana's federal scheduling has historically excluded it from pharmacy practice.
What drug interactions were identified?
The review noted that marijuana can interact with medications metabolized by similar liver enzymes, with sedating drugs, and with medications affecting cardiovascular function. Specific interactions were not well characterized at the time.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00291APA
Seamon, Matthew J; Fass, Jennifer A; Maniscalco-Feichtl, Maria; Abu-Shraie, Nada A. (2007). Medical marijuana and the developing role of the pharmacist.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 64(10), 1037-44.
MLA
Seamon, Matthew J, et al. "Medical marijuana and the developing role of the pharmacist.." American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007.
RethinkTHC
RethinkTHC Research Database. "Medical marijuana and the developing role of the pharmacist." RTHC-00291. Retrieved from https://rethinkthc.com/research/seamon-2007-medical-marijuana-and-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.